Comparative Pharmacology
Head-to-head clinical analysis: TRACRIUM versus TRACRIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRACRIUM versus TRACRIUM PRESERVATIVE FREE.
TRACRIUM vs TRACRIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and causing muscle relaxation.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking depolarization and preventing muscle contraction.
Initial: 0.3-0.6 mg/kg IV bolus. Maintenance: 0.1-0.2 mg/kg every 20-45 minutes as needed. Alternatively, continuous infusion: 0.005-0.01 mg/kg/min (5-10 mcg/kg/min).
Initial dose 0.4-0.5 mg/kg IV bolus for intubation; maintenance 0.08-0.1 mg/kg IV every 20-45 minutes as needed or continuous infusion 5-10 mcg/kg/min
None Documented
None Documented
Terminal elimination half-life: approximately 20 minutes (range 15-30 min). Clinically, this short half-life results in rapid spontaneous recovery after discontinuation, making it suitable for continuous infusion.
Terminal elimination half-life: 20-30 minutes (healthy adults). Clinically, recovery is rapid due to redistribution and Hofmann elimination; prolonged in hypothermia or acidosis.
Renal (approximately 50-60% as unchanged drug and metabolites); biliary/fecal (minor, <10%); Hofmann elimination (non-enzymatic degradation) and ester hydrolysis contribute to clearance. Total excretion is predominantly renal.
Renal: 10-20% unchanged; biliary/fecal: 50-60% as metabolites and parent drug; Hofmann elimination (non-enzymatic) accounts for ~45% of clearance.
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent